Harrow Health, Inc.
Index- P/E- EPS (ttm)-0.78 Insider Own6.30% Shs Outstand27.23M Perf Week17.78%
Market Cap182.17M Forward P/E41.01 EPS next Y0.17 Insider Trans2.95% Shs Float24.86M Perf Month1.92%
Income-21.10M PEG- EPS next Q0.01 Inst Own58.50% Short Float3.72% Perf Quarter-16.89%
Sales79.20M P/S2.30 EPS this Y-432.70% Inst Trans1.24% Short Ratio9.05 Perf Half Y-36.26%
Book/sh0.37 P/B18.62 EPS next Y318.20% ROA-20.80% Target Price17.38 Perf Year-31.31%
Cash/sh1.91 P/C3.61 EPS next 5Y15.00% ROE-138.20% 52W Range5.40 - 12.99 Perf YTD-20.25%
Dividend- P/FCF227.71 EPS past 5Y14.30% ROI3.40% 52W High-46.96% Beta0.96
Dividend %- Quick Ratio6.30 Sales past 5Y29.40% Gross Margin74.20% 52W Low27.59% ATR0.41
Employees182 Current Ratio6.80 Sales Q/Q43.50% Oper. Margin0.00% RSI (14)59.82 Volatility7.83% 6.80%
OptionableYes Debt/Eq7.12 EPS Q/Q- Profit Margin-26.70% Rel Volume1.90 Prev Close6.89
ShortableYes LT Debt/Eq7.12 EarningsMay 05 AMC Payout- Avg Volume102.32K Price6.89
Recom1.70 SMA209.32% SMA502.43% SMA200-19.34% Volume0 Change0.00%
Oct-14-21Resumed B. Riley Securities Buy $16
Sep-24-21Initiated Aegis Capital Buy $15
Jul-02-21Initiated Ladenburg Thalmann Buy $14.25
May-06-22 09:01AM  
May-05-22 04:01PM  
May-04-22 08:00AM  
Apr-22-22 08:00AM  
Apr-20-22 07:00AM  
Mar-31-22 07:00AM  
Mar-10-22 04:01PM  
Feb-24-22 08:00AM  
Feb-22-22 07:00AM  
Feb-15-22 07:00AM  
Feb-10-22 04:50PM  
Feb-08-22 08:00AM  
Feb-06-22 08:36AM  
Jan-10-22 06:45AM  
Jan-04-22 08:00AM  
Dec-30-21 10:24AM  
Dec-20-21 07:00AM  
Dec-13-21 08:00AM  
Dec-07-21 04:32PM  
Dec-06-21 11:54AM  
Nov-29-21 10:00AM  
Nov-19-21 12:20PM  
Nov-09-21 06:25PM  
Nov-07-21 08:53AM  
Oct-25-21 09:00AM  
Sep-27-21 08:26AM  
Sep-02-21 08:00AM  
Aug-18-21 07:00AM  
Aug-13-21 01:21AM  
Aug-12-21 12:45PM  
Aug-10-21 05:15PM  
Aug-05-21 10:57AM  
Aug-03-21 03:01PM  
Aug-02-21 05:50PM  
Jul-28-21 11:30AM  
Jul-27-21 07:00AM  
Jul-26-21 09:00AM  
Jul-19-21 08:00AM  
Jul-16-21 10:00AM  
Jul-15-21 08:00AM  
Jul-06-21 08:27AM  
Jun-23-21 06:34AM  
Jun-17-21 04:01PM  
Jun-14-21 05:59PM  
Jun-04-21 04:03AM  
Jun-03-21 08:15AM  
Jun-01-21 09:00AM  
May-17-21 09:00AM  
May-11-21 04:01PM  
May-05-21 04:03PM  
May-04-21 03:00PM  
Apr-27-21 09:00AM  
Apr-20-21 04:01PM  
Apr-15-21 05:00PM  
Apr-14-21 04:01PM  
Apr-05-21 05:43AM  
Mar-11-21 09:45AM  
Mar-08-21 06:05PM  
Mar-02-21 09:00AM  
Mar-01-21 04:26PM  
Feb-25-21 09:00AM  
Feb-09-21 07:00AM  
Feb-04-21 02:25AM  
Dec-18-20 11:22AM  
Dec-17-20 10:30AM  
Dec-15-20 10:30PM  
Dec-08-20 08:33AM  
Dec-03-20 07:30AM  
Nov-20-20 07:30AM  
Nov-09-20 05:35PM  
Nov-06-20 10:21AM  
Nov-02-20 12:31PM  
Oct-27-20 07:30AM  
Sep-30-20 08:00AM  
Sep-16-20 08:36AM  
Sep-11-20 11:22AM  
Sep-07-20 03:03PM  
Aug-26-20 08:16AM  
Aug-10-20 08:05PM  
Aug-07-20 11:05AM  
Aug-04-20 07:00AM  
Aug-03-20 12:31PM  
Jul-27-20 07:30AM  
Jul-24-20 10:24AM  
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Opaleye Management Inc.10% OwnerApr 13Buy6.7612,83286,7853,175,000Apr 13 06:33 PM
Opaleye Management Inc.10% OwnerApr 12Buy6.7528,557192,7173,165,000Apr 13 06:33 PM
Opaleye Management Inc.10% OwnerJan 28Buy6.896,34343,6863,140,000Jan 31 04:05 PM
BAUM MARK LChief Executive OfficerJan 20Option Exercise2.40125,000300,0001,478,547Jan 21 08:45 PM
LINDSTROM RICHARD L MDDirectorSep 24Sale10.043,90039,15666,100Sep 27 07:31 PM
LINDSTROM RICHARD L MDDirectorSep 16Sale9.025,84052,67770,000Sep 17 05:15 PM
LINDSTROM RICHARD L MDDirectorSep 15Sale9.0914,160128,71475,840Sep 17 05:15 PM
Opaleye Management Inc.10% OwnerAug 19Buy8.4552,500443,3623,135,000Aug 23 05:59 PM
Opaleye Management Inc.10% OwnerAug 18Buy8.6446,500401,9793,085,000Aug 19 07:10 PM
Opaleye Management Inc.10% OwnerAug 17Buy8.5726,000222,7193,040,000Aug 19 07:10 PM
Opaleye Management Inc.10% OwnerJul 21Buy7.609,20669,9333,015,000Jul 22 09:19 AM
Opaleye Management Inc.10% OwnerJul 20Buy7.204,92535,4603,010,500Jul 22 09:19 AM
Opaleye Management Inc.10% OwnerJul 19Buy6.975,86940,8973,005,700Jul 22 09:19 AM
Opaleye Management Inc.10% OwnerJun 18Buy8.3563,322528,6883,000,000Jun 22 11:44 AM
Opaleye Management Inc.10% OwnerJun 17Buy8.3211,26293,7012,940,200Jun 22 11:44 AM